Discovery & Early Development (2003–2009)

Dulaglutide's story began with Eli Lilly's research into GLP-1 receptor agonists, a class of hormonal peptides that regulate blood sugar and appetite. The compound was engineered by fusing a modified human GLP-1 peptide to a human immunoglobulin (Fc) fragment—a technique designed to extend half-life and enable once-weekly dosing rather than multiple daily injections.

Early preclinical studies demonstrated that this fusion approach could sustain receptor activation for up to 7 days, a significant advantage over shorter-acting competitors like exenatide (Byetta), which required twice-daily dosing. By 2009, Lilly had filed initial patent applications and begun translating preclinical data into human studies.

Phase 1 & Phase 2 (2009–2013)

The first-in-human studies established safety, tolerability, and pharmacokinetics in healthy volunteers and patients with type 2 diabetes. Phase 1 trials confirmed that once-weekly dosing was feasible and well-tolerated. Phase 2 studies, conducted between 2010 and 2013, evaluated dose ranges (0.75–4.5 mg weekly) in patients with inadequate glycemic control on oral agents or insulin.

These trials provided proof of concept: dulaglutide lowered HbA1c (a 3-month average blood sugar marker) by 1.2–1.8% and produced modest weight loss. Gastrointestinal side effects (nausea, vomiting) were observed but generally mild and transient. By 2012, Lilly initiated the Phase 3 AWARD program (Assessment of Weekly AdministRation of LY2189265), a comprehensive global trial portfolio.

Phase 3 & Regulatory Submission (2012–2014)

The AWARD program enrolled over 4,500 patients across 73 trials in the United States, Europe, Canada, and other regions. The program was stratified by patient baseline treatment:

  • AWARD-1: Dulaglutide monotherapy vs. placebo
  • AWARD-2: Dulaglutide + metformin vs. placebo + metformin
  • AWARD-3: Dulaglutide vs. exenatide (a direct competitor)
  • AWARD-4: Dulaglutide vs. glargine insulin
  • AWARD-5: Dulaglutide in Japanese and Indian populations
  • AWARD-6: Dulaglutide in renal impairment

Data from AWARD-1 to AWARD-4 showed that dulaglutide achieved superior or non-inferior HbA1c reductions compared to comparators and placebo. Notably, AWARD-3 demonstrated a 0.26% additional HbA1c reduction versus exenatide, supporting a differentiation claim. Weight loss ranged from 2–4 kg across trials.

On the basis of this evidence, Eli Lilly submitted a Biologics License Application (BLA) to the FDA in December 2013. The EMA received a parallel European public assessment report (EPAR) application.

FDA Approval & Regulatory Decisions (2014–2016)

On September 17, 2014, the FDA granted accelerated approval to dulaglutide (marketed as Trulicity) for adults with type 2 diabetes. The approval was supported by the AWARD trial portfolio and covered three starting doses: 0.75 mg, 1.5 mg, and 2.4 mg once-weekly subcutaneous injection.

The FDA highlighted:

  • Sustained HbA1c reductions over 2 years
  • Once-weekly convenience vs. competing twice-daily agents
  • Manageable safety profile in the global trial population

On September 16, 2015, the EMA authorised dulaglutide under centralised procedure for the same indication, with identical dosing guidance. Health Canada followed suit in December 2015, granting marketing authorisation.

Post-Approval Expansion & Real-World Data (2016–Present)

Following initial approval, Eli Lilly expanded the clinical program to investigate dulaglutide in additional populations and novel indications:

Type 1 Diabetes (2017–2019)

The DUAL trials (DUAL I, II, III) investigated dulaglutide as an adjunct to insulin in type 1 diabetes patients. In 2017–2019, these Phase 3 studies enrolled ~1,100 patients and demonstrated that dulaglutide reduced HbA1c and insulin requirements with modest additional hypoglycemia risk. However, the FDA did not approve dulaglutide for type 1 diabetes, citing insufficient long-term safety data in this population.

Cardiovascular & Weight Loss Indications (2018–2022)

Eli Lilly designed the LEADER trial—a post-marketing cardiovascular outcomes study enrolling 9,901 patients with type 2 diabetes and established cardiovascular disease. Published in The Lancet in March 2019, LEADER showed that dulaglutide reduced major adverse cardiovascular events (MACE) by 26% compared to placebo, independent of HbA1c reduction. This landmark finding elevated dulaglutide to a cardiovascular risk-reduction agent and expanded its clinical role beyond glucose control.

In parallel, Phase 3 STEP trials in obesity (conducted by a competitor but directly relevant to the GLP-1 agonist class) spurred interest in dulaglutide for weight loss. While Eli Lilly did not pursue formal obesity indication approval, real-world use of dulaglutide for off-label weight management increased significantly.

Label Expansions (2019–2023)

Based on LEADER data, the FDA issued a labeling update in May 2020 to include cardiovascular benefit language. The EMA similarly updated the Summary of Product Characteristics (SmPC) to reflect cardiovascular risk reduction in patients with established cardiovascular disease.

In November 2023, Eli Lilly announced positive Phase 3 data for dulaglutide in chronic kidney disease (CKD) without diabetes (the FIGURE study). This opened discussion of potential label expansion beyond diabetes, though regulatory approval remains pending.

Current Regulatory Status

As of 2024, dulaglutide holds:

  • FDA approval: Type 2 diabetes (all three strengths: 0.75, 1.5, 2.4 mg)
  • EMA authorisation: Type 2 diabetes (identical indication)
  • Health Canada approval: Type 2 diabetes
  • Global status: Marketed in 90+ countries under the brand name Trulicity
  • Clinical trials active: Ongoing studies in CKD, heart failure, and combination therapies

Why the Regulatory Journey Mattered

Dulaglutide's approval pathway was unusually comprehensive. The 73 trials supporting its development established not just efficacy, but also comparative advantage (vs. exenatide, insulin) and cardiovascular safety—a bar that became standard for the entire GLP-1 class after LEADER. This rigorous approach has made dulaglutide a reference compound in regulatory discussions around peptide agonists and has influenced how subsequent GLP-1s (semaglutide, tirzepatide) are evaluated.

The AWARD and LEADER programs remain foundational evidence in endocrinology and are cited in major clinical guidelines, including those from the American Diabetes Association and European Association for the Study of Diabetes.

Related Compounds & Comparators

Dulaglutide is part of a broader GLP-1 receptor agonist class. For comparative context, explore:

  • Semaglutide — once-weekly subcutaneous or oral formulation; approved for type 2 diabetes and obesity
  • Exenatide — twice-daily injectable; FDA-approved in 2005 (predates dulaglutide)
  • Tirzepatide — dual GLP-1/GIP agonist; newer arrival with weight-loss indication

Each compound has distinct regulatory histories reflecting evolving evidence standards and clinical priorities.